Patent intelligence · US
US 9861515
Compositions and methods relating to an occlusive polymer hydrogel
Compositions and methods relating to an occlusive polymer hydrogel
Patent details — US 9861515
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jan 9, 2018
- Expiration
- Jan 4, 2038
- Applicant
- Revolution Contraceptives LLC
- Claims
- 9
- CPC classes
- A61P, A61P15/16
Quick answer
US 9861515 (Compositions and methods relating to an occlusive polymer hydrogel) is held by Revolution Contraceptives LLC. Status: granted. Granted Jan 9, 2018. Expires Jan 4, 2038 (11 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Revolution Contraceptives LLC
- Grant date
- Expiration
- Claims
- 9
- CPC classes
- A61P, A61P15/16
More from Revolution Contraceptives LLC
Related pharmaceutical patents in our USPTO index.
-
US 12409225
Ras inhibitors
granted -
US 12403196
Ras inhibitors
granted -
US 12384750
Ras inhibitors
granted -
US 12365688
Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitors
granted -
US 12280113
Ras inhibitors
granted -
US 12258366
Bicyclic heteroaryl compounds and uses thereof
granted -
US 12252497
Ras inhibitors
granted -
US 12202845
Ras inhibitors
granted
Frequently asked questions
What is US patent 9861515?
US 9861515 (Compositions and methods relating to an occlusive polymer hydrogel) is held by Revolution Contraceptives LLC. Status: granted. Granted Jan 9, 2018. Expires Jan 4, 2038 (11 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9861515?
Revolution Contraceptives LLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 36 pharmaceutical patents for this assignee.
When does US 9861515 expire?
Our index shows an expiration date of Jan 4, 2038 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.